Retatrutide

Retatrutide (LY3437943) is an investigational, single-molecule triple agonist of the GIP, GLP-1, and glucagon receptors under evaluation in metabolic-disease research. Preclinical and early clinical literature explores effects on energy balance, body-weight regulation, glucose homeostasis, and liver/adipose biology in controlled study models.

Incretin Pathways (GIPR/GLP-1R): Co-agonism is studied for potentiating glucose-dependent insulin secretion, attenuating inappropriate glucagon during hyperglycemia, delaying gastric emptying, and enhancing central satiety signaling in hypothalamic circuits.
Glucagon Receptor (GCGR): Tuned activation is investigated for increasing energy expenditure, promoting lipid mobilization/oxidation, and modulating hepatic lipid handling; balance of GCGR with incretin tone is a key variable in dose-finding paradigms.
Downstream Readouts: Experimental endpoints commonly include changes in post-prandial glucose/insulin, gut-hormone profiles, resting energy expenditure, liver fat fraction, adiposity indices, and appetite-related neuropeptide signatures.

Energy-balance and weight-regulation models • Glucose-tolerance and mixed-meal tests • Body-composition and indirect-calorimetry studies • Hepatic steatosis/NASH frameworks • Lipid-metabolism and adipocyte signaling assays • Appetite/food-intake behavior paradigms • Pharmacokinetic/pharmacodynamic (PK/PD) modeling of multi-receptor agonism.

Revitalized Health research peptides are produced under cGMP-aligned conditions with pharmaceutical-grade inputs. Each Retatrutide lot is confirmed at ≥99% purity by HPLC with identity verified via LC-MS/MS. Lots undergo appearance/solubility checks and microbial/endotoxin screening to research-grade specifications. Batch-specific Certificates of Analysis provide full methods and results for traceability.

Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor-engagement fidelity in experimental use.

For laboratory research use only. Not intended for human consumption, therapeutic, or diagnostic application. Supplied exclusively to qualified professionals conducting controlled scientific investigations.

Identity: Retatrutide (LY3437943), a single-molecule peptide co-agonist at GIP, GLP-1, and glucagon receptors.
Mode: Incretin agonism supports glucose-dependent insulin secretion, reduced inappropriate glucagon during hyperglycemia, delayed gastric emptying, and central satiety signaling; calibrated GCGR activity is investigated for ↑ energy expenditure and lipid mobilization with hepatic fat handling effects.
Analytics: Purity by HPLC; identity by LC-MS/MS; sequence confirmation; endotoxin via LAL. PD readouts: mixed-meal/glucose-tolerance testing, indirect calorimetry, body-composition measures, MRI-PDFF for liver fat, appetite/food-intake paradigms, receptor cAMP/β-arrestin assays. Monitoring (research): GI tolerability, heart rate, glucose/insulin panels, hepatic enzymes, lipids.